RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
RETA
Delisted
RETA was delisted on the 25th of September, 2023.
119 hedge funds and large institutions have $1.28B invested in Reata Pharmaceuticals, Inc. Class A Common Stock in 2018 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 44 increasing their positions, 26 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
119
Holders Change
+26
Holders Change %
+27.96%
% of All Funds
2.72%
Holding in Top 10
7
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+133.33%
% of All Funds
0.16%
New
36
Increased
44
Reduced
26
Closed
10
Calls
$11.6M
Puts
$6.87M
Net Calls
+$4.7M
Net Calls Change
+$3.67M
Top Buyers
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$55.1M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$48.5M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$45M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$41.6M |
| 5 |
BlackRock
New York
|
+$34.7M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$25.8M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$14.2M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$7.55M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.91M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$3.93M |
